Literature DB >> 3768260

The pharmacokinetics of dapsone after oral administration to healthy volunteers.

F A Pieters, J Zuidema.   

Abstract

After oral administration of 100 mg dapsone (DDS) to 25 healthy volunteers peak serum DDS concentrations between 1.10 and 2.33 mg l-1 were reached within 0.5 to 4 h. AUCs varied from 20.3 to 75.4 mg l-1 h, while the elimination half-lives ranged from 11.5 to 29.2 h. The apparent volumes of distribution were 0.84 to 1.26 l kg-1 body weight, assuming complete bioavailability. Statistically significant differences in peak drug concentration, peak time and AUC existed between males and females. Absorption and elimination of DDS appeared to be faster than reported in other studies, suggesting differences in DDS kinetics between healthy volunteers and patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768260      PMCID: PMC1401154          DOI: 10.1111/j.1365-2125.1986.tb02924.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.

Authors:  K Lammintausta; L Kangas; R Lammintausta
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-04

2.  Absorption and excretion of 35S dapsone in dermatitis herpetiformis.

Authors:  J O Alexander; E Young; T McFadyen; N G Fraser; W P Duguid; E M Meredith
Journal:  Br J Dermatol       Date:  1970-12       Impact factor: 9.302

3.  Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients.

Authors:  E S Modderman; F W Merkus; J Zuidema; H W Hilbers; T Warndorff
Journal:  Int J Lepr Other Mycobact Dis       Date:  1983-06

4.  Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

Authors:  R A Ahmad; H J Rogers
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Pharmacokinetic observations on dapsone in dermatitis herpetiformis.

Authors:  A F Swain; R A Ahmad; H J Rogers; J N Leonard; L Fry
Journal:  Br J Dermatol       Date:  1983-01       Impact factor: 9.302

6.  A rapid method for determination of acetylation phenotype using dapsone.

Authors:  P A Philip; M S Roberts; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

7.  Oral activated charcoal and dapsone elimination.

Authors:  P J Neuvonen; E Elonen; M J Mattila
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

8.  Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.

Authors:  R A Ahmad; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  N-hydroxylation of 4,4'-diaminodiphenylsulphone (Dapsone) by liver microsomes, and in dogs and humans.

Authors:  H Uehleke; S Tabarelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

10.  Dapsone in saliva and plasma of man.

Authors:  J H Peters; J F Murray; G R Gordon; R H Gelber
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

View more
  7 in total

1.  Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.

Authors:  M D Edstein; K H Rieckmann; J R Veenendaal
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine.

Authors:  F Derouin; C Piketty; C Chastang; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

5.  Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers.

Authors:  G A Breen; J M Brocavich; J V Etzel; V Shah; P Schaefer; S Forlenza
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Treatment of refractory IgA vasculitis with dapsone: a systematic review.

Authors:  Keum Hwa Lee; Sung Hwi Hong; Jinhae Jun; Youngheun Jo; Woogyeong Jo; Dayeon Choi; Jeongho Joo; Guhyun Jung; Sunghee Ahn; Andreas Kronbichler; Michael Eisenhut; Jae Il Shin
Journal:  Clin Exp Pediatr       Date:  2019-09-24

Review 7.  Dapsone, More than an Effective Neuro and Cytoprotective Drug.

Authors:  Araceli Diaz-Ruiz; Juan Nader-Kawachi; Francisco Calderón-Estrella; Alfonso Mata-Bermudez; Laura Alvarez-Mejia; Camilo Ríos
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.